The Reemergence of Vaccine Nationalism by Rutschman, Ana Santos
Saint Louis University School of Law 
Scholarship Commons 
All Faculty Scholarship 
2020 
The Reemergence of Vaccine Nationalism 
Ana Santos Rutschman 
Saint Louis University School of Law, ana.santosrutschman@slu.edu 
Follow this and additional works at: https://scholarship.law.slu.edu/faculty 
 Part of the Clinical Epidemiology Commons, Health Law and Policy Commons, Infectious Disease 
Commons, Influenza Virus Vaccines Commons, Medical Immunology Commons, and the Virus Diseases 
Commons 
Recommended Citation 
Santos Rutschman, Ana, The Reemergence of Vaccine Nationalism (July 3, 2020). Georgetown Journal of 
International Affairs, Forthcoming, Saint Louis U. Legal Studies Research Paper No. 2020-16, Also 
available at http://dx.doi.org/10.2139/ssrn.3642858 
This Article is brought to you for free and open access by Scholarship Commons. It has been accepted for 
inclusion in All Faculty Scholarship by an authorized administrator of Scholarship Commons. For more information, 
please contact erika.cohn@slu.edu, ingah.daviscrawford@slu.edu. 
No. 2020-16 
The Reemergence of Vaccine Nationalism
Ana Santos Rutschman 
Saint Louis University - School of Law 
Georgetown Journal of International Affairs, Forthcoming
7/3/20, 11)30 AMThe Reemergence of Vaccine Nationalism - Georgetown Journal of International Affairs
Page 1 of 5https://gjia.georgetown.edu/2020/07/03/the-reemergence-of-vaccine-nationalism/
The Reemergence of Vaccine
Nationalism - Georgetown Journal of
International Affairs
Consider what happened during the flu (H1N1) pandemic in 2009. This was
the first global flu pandemic in four decades, originating in mid-April 2009 in
California. It lasted for several months and is now estimated to have caused
over 16,000 deaths. By May 2009, developed countries had negotiated pre-
production contracts that effectively allocated all doses of the vaccine that
could be produced to their domestic markets. The United States alone
negotiated the option to purchase up to 600,000 doses of H1N1 vaccines, at a
time when global manufacturing capacity for pandemic vaccines was
calculated to range between 1 to 2 billion doses. The companies that were
party to the pre-purchase agreements for H1N1 vaccines in 2009  Sanofi,
GlaxoSmithKline, and Novartis  are now involved in multiple research and
development (R&D) projects in the COVID-19 vaccine race.
In March 2020, another variation of vaccine nationalism emerged. German
newspapers reported that the United States government had initiated
conversations with CureVac, a German biotech company, to secure exclusive
rights over the companys COVID-19 vaccine candidate. While the
negotiations did not get far, the possibility prompted the German government
to quip that Germany is not for sale, further emphasizing that if a vaccine is
developed in Germany, then it is for Germany and the world.
In mid-May, a similar episode went one step further. Paul Hudson, the CEO of
Sanofi, one of the largest vaccine manufacturers in the world, stated that the
United States had the right to the largest pre-order of Sanofi COVID-19
vaccines. Although Sanofi is a French company, it received funding from the
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Biomedical Advanced Research and Development Authority in the United
States to develop a COVID-19 vaccine candidate. The existence of public
sector funding was the main reason Mr. Hudson cited as the justification for
the preferential treatment to be given to the United States market. A day later,
however, following criticism on both sides of the Atlantic, Sanofi reversed its
position and announced that no country would have priority access to
emerging COVID-19 vaccines.
Law, policy, and geopolitics have systematically given selected countries the
ability to negotiate agreements that further their interests to the detriment of
public health in less developed economies. The laws that regulate and
promote technical and scientific innovation  in particular,  intellectual property
rules   have been harmonized globally for the implementation of the same
protection standards in developed and developing countries alike. While the
current international legal infrastructure allows developing countries to adopt
policies to procure pharmaceutical products at affordable prices, developed
countries have consistently pressured the Global South to enter into bilateral
or regional trade agreements that essentially strip developing economies of
this power.
During the COVID-19 pandemic, there has been a return to international
intellectual property as a locus for offsetting some of these imbalances.
Several countries, including Chile, Ecuador, and Israel, have signaled that they
intend to preserve their ability to obtain affordable COVID-19 drugs and
vaccines through the compulsory licensing regime set forth in TRIPs article 31.
This regulation enables national governments to grant non-exclusive licenses
to third parties capable of manufacturing a drug or vaccine. While subject to
several requirements, compulsory licensing allows governments to guarantee
that their domestic markets will have access to welfare-enhancing products,
even if patent holders neglect those markets or supply their products at
prohibitively high prices. In a development that speaks to the magnitude of the
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ongoing outbreak, several powerhouse economies like Germany, Canada, and
France  but not the United States  also took steps to facilitate compulsory
licensing during COVID-19.
Mechanisms like compulsory licensing have been used sporadically in
previous public health crises, especially in connection with HIV/AIDS drugs.
However, they are unlikely to be of meaningful significance in the case of
vaccines. Very few companies  in a limited number of countries  have the
manufacturing capacity to produce vaccines. Whenever available, the first
batches of COVID-19 vaccine will be inherently limited. Nationalist policies are
bound to exacerbate this problem through unfettered use of contractual
frameworks. If allowed to proceed, these approaches will once again
disadvantage developing countries the most. In 2009, by the time developed
countries moved to donate vaccine doses to developing countries, the worst of
the pandemic had passed and no second wave was expected. A similar model
in the coronavirus pandemic would be catastrophic for many of the worlds
most vulnerable populations.
At the same time, the citizens of countries seemingly benefiting from
nationalism by reserving doses of vaccine might not fare as well as expected.
This is especially true of the United States, where Secretary of Health and
Human Services Alex Azar has stated that the government does not intend to
intervene to guarantee the affordability of coronavirus vaccines. If the
nationalism game were to be played to its fullest extent and each country
minded its own vaccine market, then the poorest and most disadvantaged
citizens in the United States  especially Black and Latino populations, who
have also shouldered the worst of the pandemic  might well have nowhere to
turn if COVID-19 vaccines are commercialized at unaffordable price points.
Similar concerns emerged during the Zika vaccine race, when the United
States Army and Sanofi entered into preliminary negotiations to manufacture a
vaccine candidate and no affordable pricing provisions were inserted into the
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contract.
The reemergence of vaccine nationalism underscores fundamental problems
of R&D and vaccine governance at the transnational level. Intellectual property
laws regulating the allocation of goods (vaccines) and principles of contractual
freedom (untamed in pre-production agreements) exacerbate bargaining
asymmetries across the developing-developed country divide. Moreover, they
illustrate how, collectively, we have come to treat vaccines as privatized
commodities, when  they should instead be understood as global public goods
 goods with benefits and/or costs that potentially extend to all countries.
Even if they are developed by private or public-private entities, global public
goods benefit populations across borders and markets and should not be
treated as purely privatizable commodities. Failure to recognize this dimension
of vaccines diminishes the socialization of their public health benefits.
In the long-run, it is critical to develop an international framework that restores
vaccine development and distribution to their public good status. This model
should prioritize the allocation of vaccine doses globally while ensuring that
they are affordable for populations in need. Moreover, such a plan should be
negotiated before a pandemic occurs, as countries, coordinating institutions,
and negotiators operate remedially and with short-term goals in mind during
crises. Without a pre-existing plan, nationalistic behaviors will likely continue
to flare up cyclically, miring the goal of making vaccines available to those who
need them the most, irrespective of geographical borders.
. . .
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innovation.
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